Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01)

Post Date

February 23rd 2009

Application Due Date

September 15th 2010

Funding Opportunity Number

RFA-HL-10-003

CFDA Number(s)

93.233
93.838

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Number of Awards

6

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $40600000

• Award Range:

  $None - $800000

Grant Description

Purpose. This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, solicits grant applications from institutions/organizations to conduct proof-of- concept Phase II clinical trials that test a novel intervention for a lung disease or a cardiopulmonary disorder from sleep that have the potential to significantly change clinical management. In addition, each application must include at least one ancillary study tightly related to the clinical question. Mechanism of Support. This FOA will utilize the NIH cooperative agreement (U01) grant mechanism. Funds Available and Anticipated Number of Awards. The NHLBI intends to commit up to $40,600,000 (total costs) over 4 years. It is anticipated that up to two awards will be made for each of 3 receipt dates for a total of four to six awards.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-10-003.html